Alexza Pharmaceuticals, Inc., or the Company, today announced that it has priced its previously announced underwritten public offering of 44,000,000 shares of common stock and warrants to purchase 44,000,000 shares of common stock.

Alexza Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration (FDA) has accepted the ADASUVE New Drug Application (NDA) as a complete, class 2 response to the FDA's action letter, with an indicated Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.

Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.

MOUNTAIN VIEW, Calif., Nov. 1, 2010 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will report results for its fiscal quarter ended September 30, 2010, on Tuesday, November 9, 2010 following the close of the U.S. financial markets.  As the Company recently held an investor ...

Alexza Pharmaceuticals, Inc. announced today that it has reacquired the U.S. and Canadian rights for AZ-004 (Staccato® loxapine) from Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.. AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

MOUNTAIN VIEW, Calif., Oct. 19 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has reacquired the U.S. and Canadian rights for AZ-004 (Staccato® loxapine) from Biovail Laboratories International SRL ("BLS"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE and TSX: VRX) ("Valeant").  AZ-004 is ...

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato® loxapine), submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg. A ...

MISSISSAUGA, Ontario, Oct. 11 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) announced today that Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 ...

MOUNTAIN VIEW, Calif., Oct. 11 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato® loxapine), submitted as Adusuve™ Staccato® (loxapine) ...

MOUNTAIN VIEW, Calif. , June 3 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that company President and CEO Thomas B. King will present during the Jefferies 2010 Global Life Sciences Conference.  The Alexza presentation will be on Thursday, June 10, 2010 ...

MOUNTAIN VIEW, Calif. , May 26 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it has obtained a committed equity financing facility under which it may sell up to $25 million of its registered common stock to Azimuth Opportunity, Ltd. over a 24-month ...

MOUNTAIN VIEW, Calif. , May 5 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that company President and CEO Thomas B. King will present during The Ninth Annual JMP Securities Research Conference.  The Alexza presentation will be on Tuesday, May 11, 2010 ...